Multi-targeted tyrosine kinase inhibitors as third-line regimen in advanced non-small cell lung cancer: a network meta-analysis

BACKGROUND: Four multi-targeted tyrosine kinase inhibitors (TKIs) including apatinib, anlotinib, fruquintinib and lenvatinib are currently available as third-line regimen for advanced non-small cell lung cancer (NSCLC) patients who failed at least two lines of systemic therapy. Limited evidence was...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Transl Med
Main Authors: Zhang, Zhonghan, Zhao, Yuanyuan, Lu, Feiteng, Hou, Xue, Ma, Yuxiang, Luo, Fan, Zeng, Kangmei, Zhao, Shen, Zhang, Yaxiong, Zhou, Ting, Yang, Yunpeng, Fang, Wenfeng, Huang, Yan, Zhang, Li, Zhao, Hongyun
Formato: Artigo
Idioma:Inglês
Publicado em: AME Publishing Company 2019
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6803172/
https://ncbi.nlm.nih.gov/pubmed/31700888
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm.2019.08.51
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados